• Vetiranary Medicine
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Tranquilizer/sedative/anesthetic options for temporary restraint of canine patients (Proceedings)

April 1, 2009
Ralph C. Harvey, DVM, MS, Dipl. ACVA

Pharmaceuticals do not take the place of clinical finesse.

Obvious (but important) Principles

• Appropriate physical exam and other evaluation as indicated

• Customize protocol for each patient's unique situation

• Pharmaceuticals do not take the place of clinical finesse

• Monitor for physiological effects and respond as needed

• Determine adequacy of recovery / fitness for return to ward/owners

• Counsel owners that recovering outpatient animals should be allowed to recover quietly and can not be trusted to respond typically for ± 24 hrs.

• Consult me or another anesthesiologist at any time for specific suggestions.

Advertisement

• Nobody likes an adventurous anesthetist!

• There are many other useful options and an infinite variety of clinical situations may occur.

A Few of Our Favorite Methods

1) Acepromazine - reliable tranquilization, not recommended for vicious or potentially dangerous animals, side effects are primarily hypotension but rarely some seizure-prone patients may develop seizures, contraindicated in shock or other hypovolemic conditions and in patients with liver disease, duration of effect 2 - 4 hrs, which is too long for most purposes.

• Ace at 0.05 to 0.2 mg/kg (0.05 to 0.1 mg/lb), max.3 mg total dose, SC, IM, IV

2) Acepromazine & Torbugesic (or other opioid) - substantial and reliable effect; not as often recommended for older/compromised patients; fairly prolonged effect, particularly if hepatic function is impaired; may not be the best choice for out-patients since return to "street fitness" often requires 4-6 hrs.

• Ace at 0.01 to 0.05 mg/kg, max.1.0 mg, SC, IM, or IV

• Torbugesic at 0.2 to 0.4 mg/kg, SC, IM, or IV

• Optional anticholinergics, to avoid or treat bradycardia:

• Glycopyrrolate at 0.005 to 0.015 mg/kg, SC, or IM

• Atropine at 0.02 to 0.05 mg/kg, SC, or IM

3) Valium (diazepam) & Torbugesic - less "heavy handed" than Ace & Torbugesic, but also a less substantial and less reliable effect; one of our favorite pre-anesthetic choices for the debilitated generic or geriatric/high risk patient; expect peak effects to last for about 30 min with return to "street- fitness" within 1-2 hrs. Midazolam (Versed) is currently taking the place of diazepam. One-half the listed dose of Valium or Versed is often adequate. Excitement and disorientation may occur and patient should not be stimulated nor trusted to remain sedate.

• Torbugesic at 0.2 to 0.4 mg/kg SC, IM, or IV. Followed by:

• Valium at 0.25 to 0.4 mg/kg IV (IV route strongly preferred)

• or Versed at 0.1 to 0.5 mg/kg SC, IM, or IV

• Optional anticholinergic:

• Glycopyrrolate at 0.005 to 0.015 mg/kg, SC, or IM

• Atropine at 0.02 to 0.05 mg/kg, SC, or IM

4) Telazol - remarkable physiologic stability, but beware of respiratory depression and potential to initiate seizures; avoid in patients with respiratory compromise and in those with hypertrophic cardiomyopathy or seizure history or certain intracranial or intraocular disorders (increases IOP and ICP). Expect fairly full recovery within 2 hours, but some residual effects are unfortunately too common.

• Telazol at 1-3 mg/lb (2-6 mg/kg) SC or IM

• Begin with lower doses for restraint

• Torbugesic at 0.1-0.2 mg/lb (0.2-0.4 mg/kg) mixed with Telazol

• May be given carefully by IV route - increases side-effects

• Optional anticholinergic to reduce salivation:

• Glycopyrrolate at 0.005 mg/lb (0.01 mg/kg) SC or IM

5) Dex-Medetomidine (Dexdomitor) – powerful sedative/hypnotic, similar to medetomidine (Domitor). Recommended for young, healthy, exercise-tolerant dogs. Patient monitoring is important. Availability of specific antagonist (Antisedan) contributes to safety and utility. Useful for examinations and brief procedures. Profound bradycardia and hypertension may occur. Tissue perfusion is decreased. Pulse oximeters may fail to detect signal. Use of atropine or other anticholinergics is controversial. We avoid the anticholinergics. Standard dose is scaled to body surface area (see box label).

6) We use a low dose Dexdomitor method (typically 0.0005 to 0.0025 mg/kg), combined with Torbugesic (0.2-0.4 mg/kg). These low doses of Dexdomitor, when combined with an opioid, are very effective. Reversal with Antisedan (by IM injection only) leaves the mild Torbugesic effect intact. Reversal is less often needed with Dexdomitor than with Domitor. Differences in duration of effect and in sedation may be related to the presence of "levo-domitor" in the earlier (Domitor) formulation.

Related Content:

Anesthesia
Rabbit endotracheal intubation: Yes, you can do it! (Part 2)
Rabbit endotracheal intubation: Yes, you can do it! (Part 2)
ABCs of dentistry: Airway, breathing, and circulation
ABCs of dentistry: Airway, breathing, and circulation
The vital value of treating patient pain
The vital value of treating patient pain

Advertisement

Latest News

Managing wounds in pet patients

Spectrum of care: protocols to support pet owners’ budgets

How to support women while still running a successful business

The Vets expands to Raleigh, NC

View More Latest News
Advertisement